Common Data Integrity Issues in Labs: A Strategic Analysis for Life Science Leaders
In 2025, documentation and record-keeping failures were cited in nearly all FDA warning letters issued to regulated laboratories. As laboratories navigate fragmented legacy systems and hybrid workflows, maintaining ALCOA++ data integrity has become increasingly challenging. The FDA’s transition to the Quality Management System Regulation (QMSR) in February 2026, alongside a significant increase in warning letters to drug manufacturers during fiscal year 2025, further underscores the urgency of robust data integrity infrastructure.
This strategic analysis provides a regulatory-aligned framework for identifying and addressing data integrity gaps before they result in Form 483 observations, production disruptions, or delayed approvals. It examines technical failure modes, current FDA and MHRA expectations, and a roadmap toward a compliant-by-design informatics architecture. By moving beyond tactical fixes, laboratories can reduce critical audit findings, strengthen operational reliability, and maintain global regulatory standing.
Read More
